Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 38 · MACD below its signal
None of the 29 investors followed here reported a position in IMRN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IMRN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for IMRN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.9 | -17.2 | 0.6 | 6.2 | 76.2 | -26.9 | 2.8 | 1.8 | 4.5 | -10.3 | +36.3% | ||
| 2025 | 20.1 | -7.0 | -5.3 | 4.4 | -5.8 | -1.8 | -6.9 | 13.0 | 3.8 | 0.0 | -10.0 | -55.4 | −55.1% |
| 2024 | -0.4 | -7.9 | 52.9 | -15.6 | 6.3 | 2.5 | 7.4 | 2.7 | 1.9 | -29.4 | -0.7 | -10.9 | −9.3% |
| 2023 | 10.1 | -14.4 | -4.3 | 13.1 | -0.9 | -3.8 | -1.0 | -7.0 | 6.5 | -13.6 | 24.0 | -11.6 | −9.9% |
| 2022 | 64.8 | -29.6 | 15.9 | -7.4 | -8.7 | -24.6 | 9.7 | 9.5 | -19.5 | -5.8 | 7.2 | -0.5 | −16.8% |
| 2021 | 8.9 | -2.8 | -11.0 | -7.0 | -13.1 | 0.0 | 0.0 | 0.0 | -18.1 | -7.6 | -11.7 | -22.8 | −60.8% |
| 2020 | -7.7 | -3.0 | -44.3 | 39.2 | -15.8 | 250.3 | 34.7 | -8.6 | -18.0 | -10.0 | 5.5 | -10.5 | +75.5% |
| 2019 | 15.8 | 12.7 | -21.8 | -3.8 | -39.2 | -7.8 | 11.9 | -24.4 | 10.4 | 11.5 | 9.5 | -0.3 | −37.4% |
| 2018 | 74.3 | -8.8 | 36.9 | -20.5 | -2.7 | 14.2 | -6.6 | 2.1 | -1.4 | -21.1 | -0.2 | -22.8 | +9.6% |
| 2017 | -33.5 | 12.6 | -18.3 | -0.6 | -3.8 | 5.2 | −38.5% |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.